首页> 外文期刊>Radiology >Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience.
【24h】

Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience.

机译:门静脉栓塞和自体CD133 +骨髓干细胞用于肝脏再生:初步经验。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To prospectively evaluate the effectiveness of portal vein embolization (PVE) and CD133(+) bone marrow stem cell (BMSC) administration to the liver, compared with PVE alone, to augment hepatic regeneration in patients with large hepatic malignancies. MATERIALS AND METHODS: The study was approved by the institutional ethics committee; informed consent was obtained. Thirteen patients underwent PVE of liver segments I and IV-VIII to stimulate hepatic regeneration prior to extended right hepatectomy. In six patients (three men, three women; mean age, 61 years; range, 46-72 years) with a future liver remnant volume (FLRV) below 25% and/or limited quality of hepatic parenchyma, PVE alone did not promise adequate proliferation. These patients underwent BMSC administration to segments II and III (group I). In seven patients (three men, four women; mean age, 69 years; range, 63-75 years) with an FLRV below 25%, PVE alone was performed (group II). Two radiologists blinded to patients' identity and each other's results measured liver and tumor volumes with helical computed tomography. Absolute, relative, and daily FLRV gains were compared by using the t test or the Wilcoxon test. RESULTS: The increase of the mean absolute FLRV in group I from 239.3 mL +/- 103.5 (standard deviation) to 417.1 mL +/- 150.4 was significantly higher than that from 286.3 mL +/- 77.1 to 395.9 mL +/- 94.1 in group II (P = .049). The relative gain of FLRV after PVE in group I (77.3% +/- 38.2) was significantly higher than that in group II (39.1% +/- 20.4) (P = .039). The daily hepatic growth rate in group I (9.5 mL/d +/- 4.3) was significantly superior to that in group II (4.1 mL/d +/- 1.9) (P = .03). Time to surgery was 27 days +/- 11 in group I and 45 days +/- 21 in group II (P = .057). CONCLUSION: In patients with malignant liver lesions, the combination of PVE with CD133(+) BMSC administration substantially increased hepatic regeneration compared with PVE alone.
机译:目的:前瞻性评估肝门静脉栓塞(PVE)和CD133(+)骨髓干细胞(BMSC)与单独使用PVE相比,在大肝恶性肿瘤患者中增强肝再生的有效性。材料与方法:该研究得到机构伦理委员会的批准。获得知情同意。 13名患者在扩大右肝切除术之前接受了肝脏I和IV-VIII段的PVE刺激肝再生。在六名未来肝残量(FLRV)低于25%和/或肝实质质量有限的患者(三名男性,三名女性;平均年龄61岁;范围46-72岁)中,仅PVE不能保证足够增殖。这些患者接受了BMSC的II和III节治疗(I组)。在FLRV低于25%的7例患者(三名男性,四名女性;平均年龄69岁;范围63-75岁)中,仅进行了PVE(第二组)。两名放射科医生对患者的身份视而不见,彼此的结果通过螺旋计算机断层扫描技术测量了肝脏和肿瘤的体积。使用t检验或Wilcoxon检验比较绝对,相对和每日FLRV的增加。结果:第一组的平均绝对FLRV从239.3 mL +/- 103.5(标准偏差)增加到417.1 mL +/- 150.4,明显高于286.3 mL +/- 77.1到395.9 mL +/- 94.1。第二组(P = .049)。 I组(77.3%+/- 38.2)PVE后FLRV的相对获益显着高于II组(39.1%+/- 20.4)(P = .039)。 I组的每日肝生长速率(9.5 mL / d +/- 4.3)明显优于II组的每日肝生长速率(4.1 mL / d +/- 1.9)(P = .03)。 I组的手术时间为27天+/- 11天,II组的手术时间为45天+/- 21天(P = .057)。结论:在恶性肝病患者中,与单独使用PVE相比,PVE与CD133(+)BMSC联合使用可显着提高肝再生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号